Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 19/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.80 |
| ▸ | ADORA2B | P29275 | 12/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4758022 | 0.99 | ADORA3 (0.79) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1389186 | 0.92 | ADORA3 (0.82) | ADORA3ADORA2AADORA1ADORA2B | |
| Hydrochloric Acid SCHEMBL4759229 | 0.91 | ADORA3 (0.81) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13745468 | 0.89 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL20694141 | 0.88 | ADORA3 (0.85) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1389221 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL15124919 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2283773 | 0.86 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| Hydrochloric Acid SCHEMBL4820060 | 0.86 | ADORA3 (0.98) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL14466107 | 0.86 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011528363-A | — | — | 2011-11-17 | — | — | JP | claimed |
| US-20110190324-A1 | METHODS OF TREATING ATHEROSCLEROSIS | MCNC ENTERPRISE FUND, L.P. | 2011-08-04 | — | — | US | claimed |
| EP-2300496-A1 | METHODS OF TREATING ATHEROSCLEROSIS | King Pharmaceuticals Research and Development Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2010009190-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20060040959-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-02-23 | — | — | US | claimed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | claimed |
| US-20110190324-A1 | METHODS OF TREATING ATHEROSCLEROSIS | MCNC ENTERPRISE FUND, L.P. | 2011-08-04 | — | — | US | disclosed |
| US-20110190324-A1 | METHODS OF TREATING ATHEROSCLEROSIS | MCNC ENTERPRISE FUND, L.P. | 2011-08-04 | — | — | US | disclosed |
| US-20110190324-A1 | METHODS OF TREATING ATHEROSCLEROSIS | MCNC ENTERPRISE FUND, L.P. | 2011-08-04 | — | — | US | disclosed |
| EP-2300496-A1 | METHODS OF TREATING ATHEROSCLEROSIS | King Pharmaceuticals Research and Development Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010009190-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009190-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090203719-A1 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | BOREA PIER ANDREA | 2009-08-13 | — | — | US | disclosed |
| US-7271171-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2007040565-A9 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RES & DEV (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007040565-A9 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RES & DEV (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007040565-A2 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20060204502-A1 | Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists | CREDIT SUISSE AG | 2006-09-14 | — | — | US | disclosed |
| US-6921825-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICUALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190324-A1 | METHODS OF TREATING ATHEROSCLEROSIS | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20060040959-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20060204502-A1 | Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists | HIF1A, HIF1AN, ADORA3 | ADORA3 3/4885ADORA2A 4/4885ADORA1 5/4885 |
| US-20090203719-A1 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | ADORA3, ADORA2A, ABCB1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 5/4885 |
| US-20030144266-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.